ACRS · Aclaris Therapeutics, Inc.

Summary

On March 10, 2026, Aclaris Therapeutics, Inc. sold 5.7 million shares of its common stock for aggregate gross proceeds of $20.0 million pursuant to its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. The shares were purchased by Frazier Life Sciences, Kalehua Capital and Adage Capital Partners LP.

Key takeaways

• Sold 5.7 million shares of common stock on March 10, 2026
• Aggregate gross proceeds of $20.0 million
• Pursuant to amended and restated sales agreement dated February 27, 2025
• Agents: Leerink Partners LLC and Cantor Fitzgerald & Co.
• Purchasers: Frazier Life Sciences, Kalehua Capital, Adage Capital Partners LP